Lilly beefs up neuroscience pipeline with $6.3B Centessa buyout

Tuesday, March 31, 2026Jonathan GardnerView original

The deal secures two sleep disorder drugs that would fill a hole in the company’s portfolio and intensify a competition with Takeda and Eisai.

Read the full article on the original site.